Stock comparison
Amgen
AMGN
Market cap
$183.12B
Sector
Healthcare
Overall winner
Halozyme Therapeutics
AMGN 2–5 HALO
Halozyme Therapeutics
HALO
Market cap
$8.1B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
AMGNvsHALO
61C
79B
81A
83A
62C
65B
72B
53D
47D
40D
71B
80C
67D
84A
Side-by-side metrics
| Metric | AMGN | HALO |
|---|---|---|
| Market cap | $183.12B | $8.1B |
| P/E (TTM) | 22.6x | 24.0x |
| EV/EBIT | 20.7x | 10.2x |
| ROIC (TTM) | 13.85% | 23.65% |
| Gross margin | 71.46% | 81.24% |
| Net margin | 20.95% | 23.13% |
| Revenue CAGR 5y | 9.05% | 33.23% |
| EPS CAGR 5y | 8.5% | -1.98% |
| Debt / Equity | 6.2x | 1.0x |
| Dividend yield | 3.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMGN leads on
- EPS CAGR 5y8.5%vs -1.98%+123%
- Dividend yield3.0%vs 0.0%+100%
- Market cap$183.12Bvs $8.1B+96%
- P/E (TTM)22.6xvs 24.0x+6%
HALO leads on
- Debt / Equity1.0xvs 6.2x+85%
- Revenue CAGR 5y33.23%vs 9.05%+73%
- EV/EBIT10.2xvs 20.7x+51%
- ROIC (TTM)23.65%vs 13.85%+41%
More like AMGN
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.